Cargando…

Determinants of gemcitabine response in pancreatic cancer: are we there?

Detalles Bibliográficos
Autores principales:	Fitzpatrick, Orla M., O’Kane, Grainne M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643581/ https://www.ncbi.nlm.nih.gov/pubmed/37969825 http://dx.doi.org/10.21037/jgo-2023-04

Ejemplares similares

Advances in the management of pancreatic ductal adenocarcinoma
por: O’Kane, Grainne M., et al.
Publicado: (2021)

Understanding the Role of Mesenchymal Stromal Cells in Treating COVID-19 Acute Respiratory Distress Syndrome
por: O’Kane, Cecilia M., et al.
Publicado: (2022)

Avancées dans la prise en charge de l’adénocarcinome canalaire pancréatique
por: O’Kane, Grainne M., et al.
Publicado: (2021)

Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going
por: Liang, Chen, et al.
Publicado: (2017)

Predictive Modeling of In Vivo Response to Gemcitabine in Pancreatic Cancer
por: Lee, James J., et al.
Publicado: (2013)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer
por: Duan, Kai, et al.
Publicado: (2021)

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
por: Barnes, Tristan A., et al.
Publicado: (2017)

Gemcitabine Combination Nano Therapies for Pancreatic Cancer
por: Samanta, Kamalika, et al.
Publicado: (2019)

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
por: Nakano, Y, et al.
Publicado: (2007)

Barriers and opportunities for gemcitabine in pancreatic cancer therapy
por: Beutel, Alica K., et al.
Publicado: (2023)

Novel Strategy with Gemcitabine for Advanced Pancreatic Cancer
por: Komori, Shuji, et al.
Publicado: (2011)

Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer
por: Min, Young Joo, et al.
Publicado: (2002)

Gemcitabine plus S-1 for metastatic pancreatic cancer
por: Zhu, Hong, et al.
Publicado: (2018)

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2018)

Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer
por: Blaauboer, Amber, et al.
Publicado: (2020)

Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer
por: Mahajan, Ujjwal M, et al.
Publicado: (2019)

Resistance to Gemcitabine in Pancreatic Cancer Is Connected to Methylglyoxal Stress and Heat Shock Response
por: Crake, Rebekah, et al.
Publicado: (2023)

Increased mitochondria are responsible for the acquisition of gemcitabine resistance in pancreatic cancer cell lines
por: Masuo, Hitoshi, et al.
Publicado: (2023)

Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
por: Ouyang, Guoqing, et al.
Publicado: (2016)

Establishment and characterization of the gemcitabine-resistant human pancreatic cancer cell line SW1990/gemcitabine
por: Yu, Yue, et al.
Publicado: (2019)

Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
por: Ma, Yang-Yang, et al.
Publicado: (2020)

Walled-off pancreatic necrosis: where are we?
por: Boškoski, Ivo, et al.
Publicado: (2014)

Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma
por: Palam, L R, et al.
Publicado: (2015)

New Perspectives for Pancreatic Cancer Treatment. Will We Be Able to Ensure Equity to Care?
por: Cobianchi, Lorenzo, et al.
Publicado: (2021)

Psychosis breakthrough on antipsychotic maintenance medication (BAMM): what can we learn?
por: Rubio, Jose M., et al.
Publicado: (2017)

Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells
por: Zhu, Xu, et al.
Publicado: (2018)

Novel discoveries targeting gemcitabine‐based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?
por: Luo, Wenhao, et al.
Publicado: (2019)

Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells
por: Lu, Jun, et al.
Publicado: (2023)

Synergistic activity of troxacitabine (Troxatyl™) and gemcitabine in pancreatic cancer
por: Damaraju, Vijaya L, et al.
Publicado: (2007)

Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
por: Habermehl, Daniel, et al.
Publicado: (2012)

Correction: Clusterin confers gemcitabine resistance in pancreatic cancer
por: Chen, Qingfeng, et al.
Publicado: (2013)

WWOX rs11644322 Polymorphism, Gemcitabine, and Pancreatic Cancer
por: Yasri, Sora, et al.
Publicado: (2017)

Gold Nanoparticles sensitize pancreatic cancer cells to gemcitabine
por: Huai, Yanyan, et al.
Publicado: (2019)

Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer
por: Yang, Jianhui, et al.
Publicado: (2021)

Phase II study of gemcitabine in patients with advanced pancreatic cancer.
por: Carmichael, J., et al.
Publicado: (1996)

Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer
por: Li, Liang, et al.
Publicado: (2016)

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
por: Mey, V, et al.
Publicado: (2006)

Astaxanthin inhibits gemcitabine-resistant human pancreatic cancer progression through EMT inhibition and gemcitabine resensitization
por: Yan, Tao, et al.
Publicado: (2017)

Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
por: Shin, Sangjin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_q6q634ae9r857thgck8uao2m0q